Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

OTC Statins: What We Have Is A Failure To Communicate

This article was originally published in The Tan Sheet

  • News
  • Daniel Healey

Executive Summary

The immediate prospects for an OTC statin may have been dampened by the lopsided Mevacor panel vote, but persistent enthusiasm among core decision-makers offers optimism in the long term

You may also be interested in...



Return of the Switch? A Fallow 2005 Sowed the Seeds for Future Switches

A Building Yea

Return of the Switch? A Fallow 2005 Sowed the Seeds for Future Switches

A Building Yea

FDAers Sink Mevacor OTC At Panel Meeting With Unflinching Critique

Two key presentations by FDA reviewers of Mevacor OTC study data may have undermined any chances of J&J/Merck's salvaging a favorable recommendation to switch the drug

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS097669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By